# A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

> **NCT06381843** · NA · COMPLETED · sponsor: **WestVac Biopharma Co., Ltd.** · enrollment: 120 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** Recombinant COVID-19 Vaccine (Sf9 Cell)
- **BIOLOGICAL:** COVID-19 Vaccine (Vero Cell), Inactivated

## Key facts

- **NCT ID:** NCT06381843
- **Lead sponsor:** WestVac Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-02
- **Primary completion:** 2023-03-29
- **Final completion:** 2023-12-30
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2024-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06381843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06381843, "A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06381843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*